A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration. - Wikidata - awgldk - TriplyDB

A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.

A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.

http://www.wikidata.org/entity/Q33892696

about

Inflammation and its role in age-related macular degeneration Transscleral sustained vasohibin-1 delivery by a novel device suppressed experimentally-induced choroidal neovascularization Soluble CD59 expressed from an adenovirus in vivo is a potent inhibitor of complement deposition on murine liver vascular endothelium AAV-mediated expression of human PRELP inhibits complement activation, choroidal neovascularization and deposition of membrane attack complex in mice Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease.Longitudinally extensive NMO spinal cord pathology produced by passive transfer of NMO-IgG in mice lacking complement inhibitor CD59.Aurintricarboxylic acid inhibits complement activation, membrane attack complex, and choroidal neovascularization in a model of macular degeneration.Topical application of PPADS inhibits complement activation and choroidal neovascularization in a model of age-related macular degeneration.Adeno-associated virus mediated delivery of a non-membrane targeted human soluble CD59 attenuates some aspects of diabetic retinopathy in mice.Local production of the alternative pathway component factor B is sufficient to promote laser-induced choroidal neovascularization.Overexpression p21WAF1/CIP1 in suppressing retinal pigment epithelial cells and progression of proliferative vitreoretinopathy via inhibition CDK2 and cyclin E Age-Related Macular Degeneration: A Disease of Systemic or Local Complement Dysregulation?Topical application of a G-Quartet aptamer targeting nucleolin attenuates choroidal neovascularization in a model of age-related macular degeneration.New Insights on Complement Inhibitor CD59 in Mouse Laser-Induced Choroidal Neovascularization: Mislocalization After Injury and Targeted Delivery for Protein Replacement.Adeno-associated virus mediated delivery of an engineered protein that combines the complement inhibitory properties of CD46, CD55 and CD59 Progress and Trends in Complement Therapeutics The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation Complement in immune and inflammatory disorders: therapeutic interventions.The role of the immune response in age-related macular degeneration Suppression of ischemia in arterial occlusive disease by JNK-promoted native collateral artery development.Matrix metalloproteinase activity creates pro-angiogenic environment in primary human retinal pigment epithelial cells exposed to complement.Next-generation therapeutic solutions for age-related macular degeneration.The role of glial cells and the complement system in retinal diseases and Alzheimer's disease: common neural degeneration mechanisms.Gene therapy for age-related macular degeneration.Structural and molecular changes in the aging choroid: implications for age-related macular degeneration.Viral-derived complement inhibitors: current status and potential role in immunomodulation.From compliment to insult: genetics of the complement system in physiology and disease in the human retina.Recent advances in the management and understanding of macular degeneration.Reducible PEG-POD/DNA Nanoparticles for Gene Transfer In Vitro and In Vivo: Application in a Mouse Model of Age-Related Macular Degeneration.A strategy to ensure safety of stem cell-derived retinal pigment epithelium cells.Adeno-Associated Viral Vector-Mediated mTOR Inhibition by Short Hairpin RNA Suppresses Laser-Induced Choroidal Neovascularization.Complement factor H deficiency results in decreased neuroretinal expression of Cd59a in aged mice.Current drug and molecular therapies for the treatment of atrophic age-related macular degeneration: phase I to phase III clinical development.Delivery of CR2-fH Using AAV Vector Therapy as Treatment Strategy in the Mouse Model of Choroidal Neovascularization.Complement-Mediated Activation of the NLRP3 Inflammasome and Its Inhibition by AAV-Mediated Delivery of CD59 in a Model of Uveitis.Complement C3-Targeted Gene Therapy Restricts Onset and Progression of Neurodegeneration in Chronic Mouse Glaucoma

P2860

Q26768520-3596EA4C-5703-47FF-A5DF-07976FBFD831 Q28487648-FDE92EAB-F877-4380-A2BF-0C0411AF40A4 Q28743243-C9D23267-02A6-4A04-A213-35A229F728A6 Q31154707-BF558C90-D0FC-486D-B446-2A74FDA92634 Q33569372-8DA40DF2-B7CC-400D-B157-AD14F74DE703 Q34173376-A05B02CB-197E-484F-AFE8-3E17989C75D6 Q35012333-203C6ABE-801B-40BD-8F0B-44B903542B77 Q35018565-2F54ED48-DC75-46F3-A374-3D58423EC602 Q35027989-1E2C4601-215A-4C2B-94FC-C312FB4224C8 Q35191438-3C10E797-C520-4F62-9013-39405DF0D605 Q35447625-637ADF8A-13F0-457A-9815-680378A0C608 Q35750545-4AC28A30-77D9-40CC-9412-A2E1B0F0D618 Q35774515-F7FBA7F5-7C3D-4238-A0E7-34C8ACE39184 Q36319522-177AA5BB-CA42-4F03-AD0C-6B0282EF0FE0 Q36380744-EF666766-C1B7-4D7F-AA35-9537B3EFFD2A Q36479278-13D1B250-7CFF-4AB3-8A62-393A3603CD54 Q36643354-1BEF6B2F-983C-4ECD-9694-45EB5A64CC39 Q36756854-42B5954F-41F6-47F5-9B7A-A948753F9F7D Q36914129-F5F36D9A-14C5-4968-B40B-D12DC4DB3921 Q37207782-F6AEC3B4-2725-4E4E-AC42-E1B11675D639 Q37716557-4456C0AB-FEDA-4339-B5C2-2F9E97F46D0C Q38138089-2F0410F6-D69A-4983-A4D9-48DE7312B63D Q38245648-493C7BCF-BFAB-49DD-851F-AD858FB2D744 Q38654588-AF53E3A0-53C1-4D52-8161-C75E89074BD5 Q38975097-B7F4E8BD-0797-404C-92B6-876C2A5D9226 Q38995165-FD58A3B0-3B7F-4F66-8F99-83215C362FC5 Q39290950-4925618C-3296-4F5E-B19F-C82F1F425D74 Q39297094-1B688E86-1E46-484D-A03E-A93BB3084135 Q40997212-66CAF70A-0708-4DE6-BFE4-49765C7A3687 Q41010977-3966445E-AB35-44C2-BC9E-875A827A4E9D Q41936178-C1E4C71A-A2B9-4A3B-83CA-A1A0F2781779 Q41974484-E28EA7C1-15BC-4F8E-9306-2B39B176A782 Q45870879-00A4389A-17A5-487A-BF93-E2FA1FE12F8A Q45875770-74DE2C99-A245-45C6-8721-1110DD6149B7 Q52313908-2FF3B43C-1646-4FFB-A7B5-21653F84658E Q57039780-5080D85A-58AD-4035-875D-9855FCF9F228

P2860

A non membrane-targeted human soluble CD59 attenuates choroidal neovascularization in a model of age related macular degeneration.

http://www.wikidata.org/entity/Q33892696

description

2011 nî lūn-bûn

@nan

2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

A non membrane-targeted human ...... related macular degeneration.

@ast

A non membrane-targeted human ...... related macular degeneration.

@en

type

label

A non membrane-targeted human ...... related macular degeneration.

@ast

A non membrane-targeted human ...... related macular degeneration.

@en

prefLabel

A non membrane-targeted human ...... related macular degeneration.

@ast

A non membrane-targeted human ...... related macular degeneration.

@en

P1433

Q33892696-6518DA7B-EB5A-4EA6-BD5B-BFF6BA0E8AA2

P1476

Q33892696-56B5C428-7F2A-421B-B1A1-C13AD0D51304

P2093

Q33892696-0D92B39D-78B3-41F8-A4F2-BC4FC8842574

Q33892696-443B68B4-EF3E-46DD-A756-799CCCF03C5A

Q33892696-529DC7F3-BBE6-437D-B681-A2AC08A20A48

P2860

Q33892696-05439597-3F28-44C6-A2B2-A3AD7F5169D4

Q33892696-0DD83B6E-AEBC-4A28-9293-348D74AB41EE

Q33892696-10D794A1-562A-4B2F-920D-A1ADF171AA08

Q33892696-144B05B2-E205-4556-9CA2-F24B096DA21D

Q33892696-14E0FBDC-6B0B-4798-A6FC-8BF91C31F17E

Q33892696-1BE41426-6141-4105-870F-D26781C1FEC7

Q33892696-1FEDB885-6E17-48CE-9F4C-B1E21190FC40

Q33892696-2C45AC06-E622-408E-B7BD-150EAD45B8F5

Q33892696-2C65EFD6-C307-4B8D-8BC6-59C63164C2E8

Q33892696-2C8DFBB2-8BB8-4590-8778-284A86152D25

P304

Q33892696-7079BB37-0630-4BB4-9E21-EA27E59B3808

P31

Q33892696-C181D691-43F8-4DC1-A5D9-5BAF58F2B5D9

P356

Q33892696-336F368B-3F2D-45CC-8684-56B7CFF40C03

P407

Q33892696-41A7B58D-CFCC-454F-B57F-8F1184640D03

P433

Q33892696-35FAA0B8-36D3-4829-8DE2-C04D28E40027

P478

Q33892696-01D8DC7F-3B3A-442E-85D5-2E948735AA23

P577

Q33892696-606BE5E2-A45D-4298-9773-FAE10DE30CF9

P5875

Q33892696-0BA8E070-FF9B-4F10-BC13-35425EDFC94E

P698

Q33892696-9668AF4B-30C0-4180-9BA3-E7A9529D7CBD

P921

Q33892696-686D5B10-03F9-45E8-A599-F724DC5AD8EA

P932

Q33892696-6F6D2524-4A90-4AC9-96B3-C67A8FA416B1

P356

JOURNAL.PONE.0019078

P1433

P1476

A non membrane-targeted human ...... related macular degeneration.

@en

P2093

Kasmir Ramo

http://www.w3.org/2001/XMLSchema#string

Rajendra Kumar-Singh

http://www.w3.org/2001/XMLSchema#string

Siobhan M Cashman

http://www.w3.org/2001/XMLSchema#string

P2860

A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration

CD59, an LY-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologous cells

Complement. First of two parts

Complement. Second of two parts

CD59, a complement regulatory protein, controls choroidal neovascularization in a mouse model of wet-type age-related macular degeneration

Interactions of soluble CD59 with the terminal complement complexes. CD59 and C9 compete for a nascent epitope on C8

Complement: a key system for immune surveillance and homeostasis

Complex interactions with several arms of the complement system dictate innate and humoral immunity to adenoviral vectors.

Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality.

Recombinant membrane-targeted form of CD59 inhibits the growth of choroidal neovascular complex in mice.

P304

e19078

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0019078

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P577

2011-04-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51107851

http://www.w3.org/2001/XMLSchema#string

P698

21552568

http://www.w3.org/2001/XMLSchema#string

P921

neovascularization

P932

3084256

http://www.w3.org/2001/XMLSchema#string